An Open Label Extension, Multi-Center Study to Evaluate the Safety of SD 101 Cream in Subjects With Epidermolysis Bullosa
Latest Information Update: 24 Mar 2026
At a glance
- Drugs Allantoin (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Adverse reactions; Registrational
- Sponsors Takeda Cambridge
Most Recent Events
- 24 Mar 2026 New trial record